Illumina (ILMN) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $1.31
- Estimate
- $1.23
- Surprise
- +6.8%
- Score at report (before → after)
- 4.9 → 5.0/10
Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.
How the report landed
Illumina (ILMN) beat the $1.23 estimate with adjusted EPS of $1.31 — a clear 6.8% upside surprise. TrendMatrix's engine moved from Buy (Wait) (4.9/10) to Hold at 5.0/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ILMN Hold at 5.2/10.
4 of the last 4 quarters beat the estimate; this quarter's +6.8% surprise compares with a +7.9% four-quarter average. Next scheduled report: 2027-02-04.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.9 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: sequencing revenue (92.0%)
- Concentration risk — Supplier: single-source suppliers
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $238.21
- Stop
- $221.54
At 42.3× trailing and 37.0× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
ILMN at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Diagnostics & Research
- Market cap
- $34.26B
- P/E (fwd)
- 37.0
- P/E (ttm)
- 42.3
- 52-week range
- $112.65–$309.35
- Off 52-week high
- 23.0%
- RSI (14)
- 38
- Volume vs avg
- 0.96×
- Score today
- 5.2/10